Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Endo International stock

ENDPQ
IE00BJ3V9050
A1XE6M

Price

0.00
Today +/-
+0
Today %
+0 %
P

Endo International stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Endo International stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Endo International stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Endo International stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Endo International's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Endo International Stock Price History

DateEndo International Price
5/1/20240.00 undefined
4/30/20240.00 undefined

Endo International Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Endo International, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Endo International from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Endo International’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Endo International. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Endo International’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Endo International’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Endo International’s growth potential.

Endo International Revenue, EBIT and net profit per share

DateEndo International RevenueEndo International EBITEndo International Net Income
2024e2.2 B undefined829.15 M undefined235.01 M undefined
20232.01 B undefined381.91 M undefined-2.45 B undefined
20222.32 B undefined259.75 M undefined-2.92 B undefined
20212.99 B undefined794.12 M undefined-613.25 M undefined
20202.9 B undefined689.4 M undefined183.94 M undefined
20192.91 B undefined581.87 M undefined-360.58 M undefined

Endo International Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201920202021202220232024e
2.912.92.992.322.012.2
--0.383.10-22.55-13.249.60
46.1652.1271.8767.6065.69-
1.351.512.151.571.320
581689794259381829
19.9423.7326.5311.1718.9537.61
-360183-613-2,923-2,449235
--150.83-434.97376.84-16.22-109.60
226.05233.65232.79234.84235.220
------
Details

Keystats

ⓘ

Revenue and Growth

The Endo International Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Endo International is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
20192020202120222023
         
1.451.211.511.020.78
467.95514.46594.82495.49389.02
47.5763.847.227.127.78
327.87352.26283.55274.5246.02
288.3269.26321.8280.78247.77
2.592.412.712.081.67
556.57495.5431.54466.38499.27
00000
010.3310.216.699.29
2.572.742.361.731.48
3.63.563.21.351.35
80.2944.7351.25123.15130.34
6.86.856.053.683.47
9.399.268.775.765.14
         
7072686768
8.98.948.958.978.98
-9,552.21-9,368.27-9,981.52-12,904.62-15,354.43
-219.09-217.75-216.45-226.94-223.76
00000
-866.54-647.94-1,243.99-4,162.17-6,597.56
240.9195.07232.75237.72195.13
662.74644.86607.7449.76342.96
516.83373.52582.332.140.7
00000
39.8240.38207.1800
1.461.251.630.690.54
8.398.318.077.848.15
31.726.0721.6313.8316.25
0.370.330.291.383.03
8.88.668.389.2311.2
10.269.9110.019.9211.73
9.399.268.775.765.14
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Endo International provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Endo International's financial health and stability.

Assets

Endo International's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Endo International must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Endo International after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Endo International's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20192020202120222023
-422183-613-2,923-2,449
612518457391306
-5-163-3-74
-0.52-0.350.090.51.66
0.430.210.492.30.91
5595345382890
14111014-10
98397411269435
-63-71-82-99-94
-60-624-59-133-49
3-55222-3344
00000
237-96-78-196-6
00000
204-108-105-513-604
-33.00-11.00-27.00-317.00-597.00
00000
243-335246-382-218
34.2325.42328.94169.47340.77
00000

Endo International stock margins

The Endo International margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Endo International. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Endo International.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Endo International's sales revenue. A higher gross margin percentage indicates that the Endo International retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Endo International's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Endo International's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Endo International's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Endo International. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Endo International's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Endo International Margin History

Endo International Gross marginEndo International Profit marginEndo International EBIT marginEndo International Profit margin
2024e65.67 %37.62 %10.66 %
202365.67 %18.99 %-121.79 %
202267.6 %11.2 %-126.06 %
202171.87 %26.53 %-20.49 %
202052.15 %23.75 %6.34 %
201946.15 %19.97 %-12.37 %

Endo International Stock Sales Revenue, EBIT, Earnings per Share

The Endo International earnings per share therefore indicates how much revenue Endo International has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Endo International earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Endo International's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Endo International’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Endo International's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Endo International Revenue, EBIT and net profit per share

DateEndo International Sales per ShareEndo International EBIT per shareEndo International Earnings per Share
2024e9.37 undefined0 undefined1 undefined
20238.55 undefined1.62 undefined-10.42 undefined
20229.87 undefined1.11 undefined-12.45 undefined
202112.86 undefined3.41 undefined-2.63 undefined
202012.42 undefined2.95 undefined0.79 undefined
201912.89 undefined2.57 undefined-1.6 undefined

Endo International business model

Endo International PLC is a global pharmaceutical company based in Ireland, specializing in the development, manufacturing, and distribution of prescription medications. The company was founded in New York City in 1920 as a small narcotic business and has since undergone significant changes and expansion through mergers and acquisitions. Endo now has its headquarters in Dublin, Ireland and a diverse portfolio of prescription drugs in various therapeutic areas. The company's business model focuses on the development and marketing of innovative and generic pharmaceuticals, medical devices, and diagnostic solutions to improve global patient health. It operates in five segments: Branded Pharmaceuticals, Generics, International Pharmaceuticals, Urology, and Specialty Products. The Branded Pharmaceuticals segment includes a wide range of prescription drugs targeting various indications, including pain relievers, hormone therapies, gastrointestinal products, and oncology treatments. Some of Endo's well-known brands include Lidoderm, Voltaren, and Percocet. The Generics division produces and distributes a variety of generic medications under different brand names, utilizing synergies within its network to reduce manufacturing costs and pass savings on to customers. The International Pharmaceuticals unit is responsible for Endo's global business, maintaining partnerships and joint ventures with partners worldwide and expanding the company's portfolio into new regions and markets. The Urology segment offers a broad spectrum of products and services for urology, including surgical and non-surgical procedures. This includes the globally top-selling transurethral resection generator, the GreenLight Laser. Endo's Specialty Products segment manufactures devices and active ingredients for critical infrastructure used in medical research and development. This unit has heavily focused on developing innovative solutions for medical challenges in recent years. Overall, Endo holds approximately 1% market share of the global pharmaceutical market. To strengthen its competitive position, the company focuses on expanding its product portfolio, increasing efficiency, and reducing costs. Endo has a strong presence in the American and European markets and is also active in emerging economies. It follows a growth strategy that emphasizes the introduction of new and innovative products to further expand its existing segments and explore new business areas. In 2020, Endo employed over 3500 employees worldwide and generated approximately $2.5 billion in revenue. The company aims to solidify its position as a leading pharmaceutical company and expand its influence in the global market. Endo International is one of the most popular companies on Eulerpool.com.

Endo International Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Endo International Revenue by Segment

Segmente2023202220212020201920182017201620152014
XIAFLEX®475.01 M USD438.68 M USD432.34 M USD316.23 M USD------
VASOSTRICT®93.18 M USD253.7 M USD901.74 M USD-------
Vasostrict®---785.65 M USD------
Specialty Products645.66 M USD621.7 M USD--------
Other Sterile Injectables236.47 M USD221.63 M USD--------
Established Products213.43 M USD229.44 M USD--------
ADRENALIN®99.91 M USD114.3 M USD--------
Specialty Products--633.15 M USD497.08 M USD519.68 M USD-----
Vasostrict®----531.74 M USD453.77 M USD----
Other Sterile Injectables--239.73 M USD199.3 M USD185.59 M USD274.64 M USD----
Established Products--260.47 M USD284.7 M USD335.73 M USD-----
ADRENALIN®--124.63 M USD152.07 M USD179.3 M USD143.49 M USD----
Total Specialty Products-----502.95 M USD----
Total Established Products-----359.88 M USD----
XIAFLEX®-----264.64 M USD----
Ertapenem for injection---65.61 M USD104.68 M USD57.67 M USD----
Other Established-----179.28 M USD----
Other Specialty-----156.61 M USD----
PERCOCET®-----122.9 M USD----
APLISOL®---36.22 M USD61.83 M USD-----
SUPPRELIN® LA-----81.71 M USD----
VOLTAREN® Gel acquisition-----57.7 M USD----
OPANA® ER----------
XIAFLEX®----327.64 M USD-----
Generic Pharmaceuticals650.35 M USD795.46 M USD740.59 M USD-------
Branded Pharmaceuticals859.09 M USD---------
International Pharmaceuticals------230.33 M USD---
U.S. Generic Pharmaceuticals----879.88 M USD1.01 B USD2.28 B USD2.56 B USD--
Sterile Injectables429.56 M USD589.63 M USD1.27 B USD-------
U.S. Branded Pharmaceuticals------957.53 M USD1.17 B USD--
U.S. Branded - Sterile Injectables----1.06 B USD929.57 M USD----
Branded Pharmaceuticals-851.14 M USD893.62 M USD-------
U.S. Branded - Specialty & Established Pharmaceuticals----855.4 M USD862.83 M USD----
International Pharmaceuticals72.52 M USD82.64 M USD92.91 M USD-115.95 M USD142.47 M USD-279.37 M USD--
U.S. Generic Pharmaceuticals--------1.67 B USD-
U.S. Branded Pharmaceuticals--------1.28 B USD-
Generic Pharmaceuticals---783.11 M USD------
International Pharmaceuticals--------311.7 M USD-
Sterile Injectables---1.24 B USD------
U.S. Branded Pharmaceuticals---------969.44 M USD
Branded Pharmaceuticals---781.78 M USD------
International Pharmaceuticals---99.34 M USD------
U.S. Generic Pharmaceuticals---------1.14 B USD
International Pharmaceuticals---------270.43 M USD
Devices---------177.05 M USD
Operating Segments---------2.88 B USD

Endo International SWOT Analysis

Strengths

1. Established market presence: Endo International PLC has a strong foothold in the pharmaceutical industry, with a well-known brand and a wide range of products.

2. Diverse product portfolio: The company offers a diverse range of pharmaceuticals, including branded, generic, and over-the-counter drugs, catering to various medical needs.

3. Strong research and development capabilities: Endo International PLC invests significantly in research and development, allowing for the development of innovative products and treatments.

Weaknesses

1. Patent expiration: The company faces the challenge of patent expirations, leading to increased competition from generic drug manufacturers and potential revenue loss.

2. Dependence on key products: Endo International PLC relies heavily on a few key products for a significant portion of its revenue, making it vulnerable to any decline in their sales.

3. Legal and compliance issues: The company has faced legal and compliance challenges in the past, resulting in financial penalties and damage to its reputation.

Opportunities

1. Emerging markets: Expansion into emerging markets offers growth opportunities for Endo International PLC, as increasing healthcare access and demand for pharmaceuticals present a vast consumer base.

2. Focus on specialty drugs: The company can focus on developing and marketing specialty drugs, which often have higher profit margins and lower competition than traditional medications.

3. Strategic partnerships and acquisitions: Collaborating with or acquiring complementary businesses can enable Endo International PLC to broaden its product offerings and increase market share.

Threats

1. Intense competition: The pharmaceutical industry is highly competitive, and Endo International PLC faces competition from both established pharmaceutical companies and emerging players.

2. Regulatory changes: Changes in regulations can impact the company's operations, pricing, and ability to launch new products, potentially affecting its profitability.

3. Pricing pressures: Endo International PLC faces pricing pressures from healthcare providers, insurers, and government agencies, which can impact its ability to maintain margins and profitability.

Endo International Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Endo International historical P/E ratio, EBIT multiple, and P/S ratio

Endo International shares outstanding

The number of shares was Endo International in 2023 — This indicates how many shares 235.219 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Endo International earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Endo International's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Endo International’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Endo International's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Endo International.

Endo International latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20220.38 0.47  (23 %)2022 Q3
6/30/2022-0.14 0.03  (121.11 %)2022 Q2
3/31/20220.45 0.66  (45.09 %)2022 Q1
12/31/20210.69 0.84  (21.7 %)2021 Q4
9/30/20210.5 0.8  (61.62 %)2021 Q3
6/30/20210.49 0.65  (32.11 %)2021 Q2
3/31/20210.49 0.73  (49.07 %)2021 Q1
12/31/20200.49 0.75  (52.63 %)2020 Q4
9/30/20200.14 0.52  (260.86 %)2020 Q3
6/30/20200.35 0.65  (86.19 %)2020 Q2
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the Endo International stock

Eulerpool World ESG Rating (EESG©)

52/ 100

🌱 Environment

56

👫 Social

61

🏛️ Governance

40

Environment

Scope 1 - Direct Emissions
16,872
Scope 2 - Indirect emissions from purchased energy
43,967
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
60,839
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees32
Percentage of women in management—
Percentage of Asian employees12
Share of Asian management—
Percentage of Hispanic/Latino employees10
Hispano/Latino Management share—
Percentage of Black employees9
Black Management Share—
Percentage of white employees69
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic❌

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law✅

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Endo International shareholders

%
Name
Stocks
Change
Date
0.30802 % BlackRock Financial Management, Inc.724,513010/31/2023
0.21027 % Tekla Capital Management LLC_NLE494,607494,6079/30/2023
0.21027 % abrdn Inc.494,607494,60712/31/2023
0.17943 % Coleman (Blaise)422,06604/12/2023
0.15116 % Hyatt (Michael)355,56004/12/2023
0.14926 % Maletta (Matthew Joseph)351,08504/12/2023
0.04661 % Hutson (Nancy J)109,625-6,5154/12/2023
0.04253 % Cooke (Shane M)100,03404/12/2023
0.04205 % Montague (William P)98,917-23,1084/12/2023
0.01623 % Barberio (Mark G.)38,18704/12/2023
1
2
3
4
5
...
10

Endo International Executives and Management Board

Mr. Blaise Coleman49
Endo International President, Chief Executive Officer, Director (since 2016)
Compensation 12.85 M
Mr. Mark Bradley54
Endo International Chief Financial Officer, Executive Vice President
Compensation 7.98 M
Mr. Patrick Barry55
Endo International Executive Vice President, President, Global Commercial Operations
Compensation 7.78 M
Dr. James Tursi58
Endo International Executive Vice President - Global Research and Development
Compensation 6.36 M
Mr. Matthew Maletta52
Endo International Executive Vice President, Chief Legal Officer, Company Secretary
Compensation 4.25 M
1
2
3

Most common questions regarding Endo International

What values and corporate philosophy does Endo International represent?

Endo International PLC represents values of innovation, integrity, and patient-centered care in the healthcare industry. With a corporate philosophy focused on delivering quality products and improving patient outcomes, Endo International strives to create value for all stakeholders. The company is committed to developing and commercializing innovative solutions to address unmet medical needs. Endo International is dedicated to fostering a culture of ethical conduct, accountability, and transparency in its operations. By prioritizing patient well-being, Endo International aims to make a positive impact on healthcare and enhance the quality of life for individuals worldwide.

In which countries and regions is Endo International primarily present?

Endo International PLC is primarily present in various countries and regions across the globe. These include the United States, Canada, Latin America, Europe, the Middle East, Africa, and Asia. With its global presence, Endo International PLC has established itself as a leading pharmaceutical company serving patients worldwide.

What significant milestones has the company Endo International achieved?

Endo International PLC has achieved several significant milestones in its history. The company has successfully expanded its product portfolio and entered new markets, enhancing its global presence. Endo International PLC has also demonstrated a strong commitment to innovation, developing and launching advanced pharmaceutical products that address unmet medical needs. The company's dedication to quality and patient welfare has earned it several accolades and certifications, strengthening its reputation in the industry. Endo International PLC's consistent financial growth and strategic acquisitions have further solidified its position as a leading player in the pharmaceutical sector.

What is the history and background of the company Endo International?

Endo International PLC is a leading global specialty pharmaceutical company that focuses on developing, manufacturing, and distributing innovative healthcare solutions. Established in 1997, Endo International has grown to become a recognized name in the pharmaceutical industry. With a strong commitment to improving patients' lives, the company offers a diverse portfolio of products in various therapeutic areas, including pain management, urology, endocrinology, and more. Endo International's history is marked by strategic acquisitions and collaborations, enabling them to expand their capabilities and reach. With a dedication to delivering high-quality, accessible medications, Endo International PLC continues to make significant contributions to the healthcare sector.

Who are the main competitors of Endo International in the market?

The main competitors of Endo International PLC in the market are Johnson & Johnson, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

In which industries is Endo International primarily active?

Endo International PLC is primarily active in the pharmaceutical industry. As a leading global specialty pharmaceutical company, Endo International PLC focuses on developing, manufacturing, and marketing a wide range of branded and generic prescription medicines. With a diverse portfolio of products, Endo International PLC specializes in various therapeutic areas including pain management, urology, and oncology. The company's dedication to innovation and commitment to improving patient care has positioned Endo International PLC as a key player in the pharmaceutical industry. Through its comprehensive offerings, Endo International PLC aims to address the evolving needs of patients worldwide.

What is the business model of Endo International?

Endo International PLC operates as a specialty pharmaceutical company. The company focuses on providing innovative solutions for patients and physicians in areas such as pain management, urology, and endocrinology. Endo combines its global capabilities and portfolio of branded and generic pharmaceuticals to deliver high-quality, reliable medications. With a commitment to research and development, Endo strives to address unmet medical needs and enhance patient outcomes. The business model of Endo International PLC centers on delivering effective and accessible healthcare solutions to improve the lives of individuals worldwide.

What is the P/E ratio of Endo International 2024?

The Endo International P/E ratio is 0.

What is the P/S ratio of Endo International 2024?

The Endo International P/S ratio is 0.

What is the AlleAktien quality score of Endo International?

The AlleAktien quality score for Endo International is 2/10.

What is the revenue of Endo International 2024?

The expected Endo International revenue is 2.2 B USD.

How high is the profit of Endo International 2024?

The expected Endo International profit is 235.01 M USD.

What is the business model of Endo International

Endo International PLC is a global pharmaceutical company headquartered in Dublin, Ireland. The company has various business areas and specializes in the development and marketing of prescription drugs and generics. An important business area for Endo is urology and endocrinology. In this field, the company offers solutions for the treatment of conditions such as prostate cancer, bladder cancer, testicular cancer, and other hormonal disorders. Products in the urology and endocrinology sector include Vantas, a depot preparation for hormone therapy in prostate cancer, and Supprelin LA, an implant for the treatment of precocious puberty in boys. Another important area for Endo is pain management. In this field, the company offers various medications to treat acute and chronic pain. Examples include Opana, a strong analgesic for the treatment of chronic pain, and Percocet, a painkiller consisting of oxycodone and paracetamol. Endo also has a business area focused on the treatment of central nervous system disorders. Here, the company develops and markets medications for conditions such as Parkinson's disease, schizophrenia, bipolar disorder, and epilepsy. Products in this sector include Lidoderm, a medication for the treatment of pain associated with shingles, and Stalevo, a combination preparation for the treatment of Parkinson's. Endo is also involved in the generic drug sector and offers a wide range of generics. This includes generics of medications for the treatment of diabetes, hypertension, infections, and other conditions. The generic sector is an important growth market for Endo, and the company is committed to expanding its portfolio in this area. Endo follows a diversified business model and operates in various geographical regions. The company is heavily invested in research and development to expand its portfolio and bring innovative medications to the market. Despite challenges in the field of pain management, the company is well positioned to achieve future growth. Overall, Endo International PLC is a strong pharmaceutical company with a broad portfolio of prescription drugs and generics. The company relies on diversification and innovation to continue playing a significant role in the pharmaceutical industry.

What is the Endo International dividend?

Endo International pays a dividend of 0 USD distributed over payouts per year.

How often does Endo International pay dividends?

The dividend cannot currently be calculated for Endo International or the company does not pay out a dividend.

What is the Endo International ISIN?

The ISIN of Endo International is IE00BJ3V9050.

What is the Endo International WKN?

The WKN of Endo International is A1XE6M.

What is the Endo International ticker?

The ticker of Endo International is ENDPQ.

How much dividend does Endo International pay?

Over the past 12 months, Endo International paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Endo International is expected to pay a dividend of 0 USD.

What is the dividend yield of Endo International?

The current dividend yield of Endo International is .

When does Endo International pay dividends?

Endo International pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Endo International?

Endo International paid dividends every year for the past 0 years.

What is the dividend of Endo International?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Endo International located?

Endo International is assigned to the 'Health' sector.

Wann musste ich die Aktien von Endo International kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Endo International from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Endo International pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Endo International in the year 2023?

In the year 2023, Endo International distributed 0 USD as dividends.

In which currency does Endo International pay out the dividend?

The dividends of Endo International are distributed in USD.

All fundamentals about Endo International

Our stock analysis for Endo International Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Endo International Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.